US 12,390,492 B2
Compositions and methods for treating age-related macular degeneration
Aya Barzelay, Ramat Gan (IL); Adiel Barak, Hod Hasharon (IL); and Anat Loewenstein, Tel Aviv (IL)
Appl. No. 16/978,735
Filed by Aya Barzelay, Ramat Gan (IL); Adiel Barak, Hod Hasharon (IL); and Anat Loewenstein, Tel Aviv (IL)
PCT Filed Mar. 7, 2019, PCT No. PCT/IL2019/050258
§ 371(c)(1), (2) Date Sep. 7, 2020,
PCT Pub. No. WO2019/171386, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/639,648, filed on Mar. 7, 2018.
Prior Publication US 2020/0397825 A1, Dec. 24, 2020
Int. Cl. A61K 35/28 (2015.01); A61P 27/02 (2006.01); C12N 5/077 (2010.01); C12N 5/0775 (2010.01)
CPC A61K 35/28 (2013.01) [A61P 27/02 (2018.01); C12N 5/0654 (2013.01); C12N 5/0667 (2013.01); C12N 2500/02 (2013.01); C12N 2502/1382 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A composition comprising orbital fat derived mesenchymal cells (OASC) and a carrier, wherein at least 70% of said OASCs within said composition express CD73, at least 70% of said OASCs lack expression of CD45, 30 to 60% of said OASCs express CD90, and 40 to 70% of said OASCs express CD105, and wherein said OASCs are characterized by 2-fold to 3-fold increased expression of a neurotrophic cytokine being hepatocyte growth factor (HGF) compared to abdominal fat derived mesenchymal cells.